Thrombospondin-1 (TSP-1), a natural inhibitor of angiogenesis, acts directly on endothelial cells (EC) via CD36 to inhibit their migration and morphogenesis induced by basic fibroblast growth factor. Here we show that CD36 triggered by TSP-1 inhibits in vitro angiogenesis stimulated by vascular endothelial growth factor-A (VEGF-A). To demonstrate that the TSP-1 inhibitory signal was mediated by CD36, we transduced CD36 in CD36-deficient endothelial cells. Both TSP-1 and the agonist anti-CD36 mAb SMO, which mimics TSP-1 activity, reduced the VEGF-A 165 -induced migration and sprouting of CD36-ECs. To address the mechanisms by which CD36 may exert its angiostatic function, we investigated the functional components of the C-terminal cytoplasmic tail by site-directed mutagenesis. Our results indicate that C464, R467, and K469 of CD36 are required for the inhibitory activity of TSP-1. In contrast, point mutation of C466 did not alter TSP-1 ability to inhibit EC migration and sprouting. Moreover, we show that activation of CD36 by TSP-1 down-modulates the VEGF receptor-2 (VEGFR-2) and p38 mitogenassociated protein kinase phosphorylation induced by VEGF-A 165 , and this effect was specifically abolished by point mutation at C464. These results identify specific amino acids of the C-terminal cytoplasmic tail of CD36 crucial for the in vitro angiostatic activity of TSP-1 and extend our knowledge of regulation of VEGFR-2-mediated biological activities on ECs.
as thrombospondin (TSP)-1 and -2 (12, 13) . A general molecular mechanism of the angiostatic activity of these molecules is based on their ability to trigger a genetic program leading to EC apoptosis (14, 15) .
TSP-1 is a 450-kDa glycoprotein secreted by many cells and inhibits tumor growth and metastasis formation (16). TSP-1 is a potent inhibitor of in vivo angiogenesis in rat and murine corneal pocket, chick chorioallantoid membrane angiogenesis assays, and wound and tumor assays (17) (18) (19) . In vitro and in vivo experiments demonstrate that TSP-1 can make ECs unable to grow, sprout, and migrate in response to different angiogenic inducers (18, (20) (21) (22) (23) . The procollagen domain and the type 1 repeats have been identified as the molecular region involved in the angiostatic activity of TSP-1 (17). Two peptides derived from these regions inhibit in vivo neovascularization in corneas and sponge implants by a direct activity on CD36 expressed on ECs (22). Two additional sets of peptides belonging to TSP-1 sequence indirectly block proangiogenic activities of ECs by competing with basic fibroblast growth factor (bFGF) for cell surface heparin binding sites or activating transforming growth factor-β (24, 25). Besides CD36, TSP-1 may interact with integrins αvβ3 (26), α3β1 (27, 28), α4β1 (29) , α6β1 (30), integrinassociated protein (31) , heparan sulfate proteoglycans (32) , and low-density lipoprotein related receptor (33) , which are expressed on EC surface.
CD36 is a transmembrane glycoprotein that has been shown to participate in multiple biological functions, including platelet aggregation, inhibition of angiogenesis, uptake of oxidized lowdensity lipoprotein (oxLDL) and long chain fatty acids, cell adhesion, and vascular sequestration of Plasmodium falciparum-infected erythrocytes (34) . CD36 is necessary to inhibit in vitro EC migration and formation of capillary-like structure by TSP-1 (22). Furthermore, it plays an essential role in vivo, as demonstrated by the impairment of angiostatic effect exerted by TSP-1 in mice with targeted deletion of CD36 gene (35) . CD36 is expressed by several cell types including erythrocyte precursors, monocytes, dendritic cells, mammary epithelial cells, myocytes, adypocytes, platelets, and microvascular ECs (34, 36, 37) . Its sequence is characterized by two hydrophobic domains located at the N terminus and at the C-terminus, both acting as transmembrane insertion. In ECs and platelets, CD36 has been shown to associate with the Src family protein tyrosine kinases Fyn, Yes, and Lyn (37, 38) . Fyn (35) has been reported to participate in CD36-dependent inhibition of angiogenesis promoted by TSP-1. However, the biochemical mechanisms by which the cytoplasmic tail of CD36 exerts its angiostatic activity remain to be elucidated.
Here we report that CD36 is a negative regulator of VEGF-A 165 -mediated in vitro angiogenesis. Indeed we investigated the molecular features of the C-terminal cytoplasmic tail necessary to mediate the inhibitory effects of TSP-1.
MATERIALS AND METHODS

Cell preparation and culture
Human ECs were isolated from umbilical cord veins, characterized, and grown in Medium 199 (Sigma) containing 20% FCS (Invitrogen), bovine brain extract, heparin, and penicillinstreptomycin, as described previously (39) . They were used at early passages (I-IV). Human dermal microvascular endothelial cells (HMEC) were obtained from Clonetics and grown in EGM-2 also from Clonetics. Phoenix cells were maintained in DMEM supplemented with 10% FCS and penicillin-streptomycin (Sigma; ref 40) . TSP-1 from human platelets was a gift from Dr. Taraboletti (20). In some experiments, we used commercial TSP-1 (Sigma). oxLDL was prepared from commercial low-density lipoprotein (Sigma) as described previously (41) .
Retroviral vector construct and EC infection
The cDNA of CD36 wild-type and CD36 mutants (42, 43) was subcloned by polymerase chain reaction in pCR2.1 plasmid (Invitrogen), sequenced, and subcloned into EcoRI/EcoRI sites of the retroviral vector Pinco containing green fluorescence protein cDNA as tracking marker (40) . The CD36 and GFP cDNA are under control of LTR and CMV, respectively, promoters. Amphotropic cell line Phoenix was transfected with Pinco, Pinco-CD36, and Pinco-CD36 mutants to producing retroviral supernatant with high viral titer. The virus-containing medium was collected, filtered (0.45 μm filter, Millipore), and supplemented with 4 μg/ml polybrene (Sigma). EC, at II passage, were plated in 150 mm tissue culture dishes for infections, and the culture medium was replaced by the appropriate viral supernatant. The target cells were incubated for 5 h at 37°C and 5% CO 2 , and then the supernatant was replaced by EC growth medium. After 72 h after infection, cells were analyzed for GFP expression by flow cytometry.
Flow cytometry
Transduced ECs were grown for at least 72 h before FACS analysis to reach steady-state GFP and CD36 expression detached by trypsin-EDTA treatment, washed twice with PBS, incubated with JCD36P monoclonal antibody (MoAb; Peli-Cluster, Amsterdam, the Netherlands), and revealed by goat anti-mouse Ig R-phycoerythrin conjugated (Southern Biotechnology Associates). Analysis was performed on FACScan (Becton-Dickinson).
Immunoprecipitation and immunoblot analysis
For immunoprecipitation, confluent cells were washed three times with phosphate buffer saline containing 1 mM Na orthovanadate and lysed at 4°C in a 25 mM HEPES buffer pH 7.6, containing 150 mM NaCl, 1% TritonX-100 or Brij97, and protease and phosphates inhibitors (pepstatin, 50 μg/ml; leupeptin, 50 μg/ml; aprotinin, 10 μg/ml; PMSF, 2 mM; soybean trypsin inhibitor, 500 μg/ml; ZnCl 2 100 μM, Na ortho-vanadate 1 mM). After centrifugation (20 min, 10,000 g), supernatants were precleared by incubation for 1 h with protein A-Sepharose (Sigma). Samples (700 μg of proteins) were incubated either with NL07 MoAb anti-CD36 or MoAb antiintegrin β1 (Chemicon) and antigen immunoprecipitated as described previously (44) or incubated with 5 μl of polyclonal antibody anti-VEGFR-2 (Santa Cruz Biotechnology), for 1 h, and immune complexes were recovered on protein A-Sepharose. Beads were washed four times with lysis buffer, twice with the same buffer without detergents and once with tris-buffered saline, and detected by immunoblot. Proteins were separated by SDS-PAGE electrophoresis, transferred to PVDF membrane (Millipore), incubated with MoAb anti-CD36 mouse Mo91 (1:1000) (45), rabbit serum anti-VEGFR-2 (Santa Cruz Biotechnology), MoAb antiphosphotyrosine 4G10 (Upstate Biotechnology), MoAb anti-integrin α5β1 (Chemicon), rabbit serum anti-phospho p38MAPK, anti-p38MAPK, anti-ERK1/2, and MoAb anti-phosphoERK1/2 (Cell Signaling) and visualized by ECL system (Pharmacia-Amersham-Biotech). 
EC chemotaxis
Chemotaxis assays were performed by Boyden's chamber as described previously (46) . Briefly, polycarbonate filters with 8 µm pore size (Neuroprobe, Pleasanton, CA) were coated with gelatin (0.1% for 6 h at room temperature). VEGF-A 165 (R&D Systems) in medium supplemented with 2% bovine serum albumin were seeded in the lower compartment of the chamber, and 2 × 10 2 cells resuspended in medium containing 2% FCS were then seeded in the upper compartment. After 5 h incubation at 37°C, the upper surface of the filter was scraped with a rubber policeman, and the filters were fixed and stained with Diff-Quick (Baxter Spa, Rome, Italy). Ten fields in the lower surface of the filters were counted after coding samples at ×400 magnification. Inhibition of the VEGF-A 165 -induced EC migration was tested by adding in the lower chamber either the agonist mAb SMO (1 μg/ml; Sigma), TSP-1 (10 nM), and oxLDL (2 μg/ml).
Endothelial spheroid model
ECs were assembled on methylcellulose spheroids according to Korff and Augustin (47) . Briefly, ECs were trypsinized, counted, and suspended at a density of 4 cells/μl in culture medium containing 20% Methocel (Sigma) (20 ml of Methocel stock with 80 ml of M-199 20% FCS, 0.1 mg/ml heparin, and 0.1 mg/ml brain extract). Eight hundred cells were seeded into nonadherent round-bottom 96-well plates, and cultured overnight at 37°C. The following day the formed spheroids were harvested, centrifuged for 15' at 300 g at room temperature, and embedded into collagen gels. A diluted collagen-I (Sigma, from rat tail) solution was prepared before use by mixing 7 vol collagen (equilibrated to 3 mg/ml in sterile 0.2% acetic acid pH 3, 4°C), 1 vol 10 × M-199, 1 vol 0.1 N NaOH, and 1 vol 0.2 M HEPES pH 7.3. The EC spheroids were suspended in 200 μl of M-199 medium containing 40% FCS, 1.2% (v/w) methylcellulose with or without 30 ng/ml VEGF-A 165 , and mixed with an equal volume of diluted collagen solution. The spheroids were rapidly transferred into 96-well plates (400 μl/well) to allow polymerizing. Capillary-like sprouts were quantitated by automatic measurement of the cumulative length of all sprouts originating from the central plain of an individual spheroid using the ImageProPlus 4.0 imaging software (Media Cybernetics).
Apoptosis measurements
To induce apoptosis, endothelial cells were treated were seeded in a 96-well plate in 100 µl serum-free M199 medium supplemented with 1% BSA. Cells were cultured for 24 h either in the presence or absence of 20 ng/ml of VEGF-A, mAb SMO (1 μg/ml; Sigma), and TSP-1 (10 nM). Apoptosis was quantified by measuring cytoplasmic histone-associated DNA oligonucleosome fragments with Cell Death Detection ELISA plus (Roche Diagnostic). Cell apoptosis was quantified by measuring DNA fragmentation as oligonucleosomes OD (absorbance A 405nm -A 490nm ).
RESULTS
Infection of ECs with retrovirus carrying CD36
CD36 is expressed on microvascular ECs but not on ECs from large vessels (36) , thus providing a useful tool to specifically assess CD36-dependent cellular functions. Therefore, we infected human ECs from umbilical cord veins at high efficiency, using a retroviral vector carrying gfp and CD36 under control of CMV and LTR, respectively, promoters. FACS analysis of ECs infected with mock vector (EC-Pinco) showed high expression level of GFP, whereas CD36 was undetectable (Fig. 1A) . EC-CD36 expressed both GFP and CD36 as assessed by FACS and immunoblot analysis (Fig. 1A-B ). EC populations with >80% of GFP positive cells were analyzed for CD36 expression by FACS and employed for further experiments, within 4 wk after infection, when at least 60% of the cells expressed CD36 on the cell membrane. In some experiments, we followed the GFP and CD36 expression level at 2 and 4 wk after infection and we did not observe any significant variation in the expression of these proteins (data not shown).
TSP-1 inhibits VEGF-A 165 -induced migration and in vitro angiogenesis
The angiogenesis process requires distinct cellular activities including migration, proliferation, differentiation, and protease activation (3). When tested in chemotaxis assay, EC-CD36 were sensitive to a gradient of VEGF-A 165 and their motility was inhibited by TSP-1 at 10 nM. In contrast, EC-Pinco responded to VEGF-A 165 but not to TSP-1. Additionally, the agonist anti-CD36 mAb SMO, which mimics TSP-1 activity (22), reduced the VEGF-A 165 -induced migration of EC-CD36 but not that of EC-Pinco ( Fig. 2A) . The oxidized low-density lipoproteins, which are a TSP-1 not related ligands, inhibited VEGF-A 165 -induced migration of EC-CD36 ( Fig. 2A ).
The effect of CD36 expression in ECs was also evaluated in an in vitro angiogenesis assay where spheroids of ECs were embedded in collagen gel (47) . In presence of VEGF-A 165 , EC-Pinco and EC-CD36 sprout and invade the surrounding collagen gel forming a ring of capillary-like structures. The addition of TSP-1 (10 nM) completely inhibited EC-CD36 sprouting without affecting EC-Pinco (Fig. 2C) . Similar results were obtained by the addition of anti-CD36 MoAb SMO to the collagen gel (Fig. 2C ).
Because it has been reported that TSP-1 angiostatic activity is partially mediated by induction of cell apoptosis (35), we examined the ability of TSP-1 to induce apoptosis of EC-CD36. Unexpectedly, the apoptosis rate induced by serum deprivation of both EC-Pinco and EC-CD36 was not modified by the addition of TSP-1 (Fig. 2B ). In the same way, the presence of VEGF-A in the culture medium protects EC-pinco and EC-CD36 from apoptosis but this protective effect was not reduced by TSP-1 (Fig. 2B) .
Expression of CD36 mutants in ECs
The intracellular C-terminal tail of CD36 is constituted by nine amino acid residues, among these the CXCX 5 K motif is reminiscent of the sequence of the cytoplasmic tails of the CD4 and CD8 antigens that mediate the association with signaling molecule (48) . Furthermore, it has been proposed that the C-terminal cytoplasmic tail of CD36 mediates its interaction with focal adhesion kinase (49) . For these reasons, we focused our attention on the C-terminal intracytoplasmic tail features. To elucidate the cytosolic molecular determinants of CD36 relevant for its angiostatic activities, ECs were engineered with stable retroviral expression vector bearing different CD36 constructs, with point, nonconservative mutations of C464, C466, R467, and K469 (Fig. 3A) . Surface expression of the different CD36 constructs in ECs was assessed by FACS analysis using anti-CD36 MoAb, which recognizes an extracellular epitope (45) . All infected ECs expressed GFP with high efficiency (data not shown) and at least 60% of them CD36 on their surface (Fig. 3B) . The expression of CD36 was also assessed by immunoprecipitation and immunoblotting analysis, which showed the presence of a 88 kDa band recognized by MoAb anti-CD36. CD36 expression in these cells was similar to that detected in human dermal microvascular endothelial cells (Fig. 3C ).
Point mutations of C-terminal CD36 intracellular tail affect TSP-1 inhibition of EC migration and in vitro angiogenesis
We were interested to look at the effects of TSP-1 on migration and differentiation into capillarylike structures of ECs engineered with different CD36 constructs. When tested in Boyden's chamber assay in the presence of a VEGF-A 165 gradient, the CD36 mutants C464S and K469A were not sensitive to TSP-1 inhibition. In contrast, TSP-1 was able to inhibit the VEGF-A 165 activity in ECs expressing CD36 mutants on C466 (C466S) and R467 (R467G) (Fig. 4A) .
Similar results were obtained when the effect of TSP-1 was evaluated in sprouting assay. All cell mutants examined responded to VEGF-A 165 as EC-Pinco or EC-CD36. The addition of TSP-1 blocked the capillary sprouting from spheroid of EC-CD36 and EC-CD36
C466S
. In contrast, EC-CD36
C464S
, EC-CD36
R467G
, and EC-CD36
K469A formed tubular structures also in the presence of TSP-1, suggesting that these amino acids are required for CD36-mediated intracellular signal (Fig. 4B) . The effect of the agonist monoclonal antibody anti-CD36 (SMO) was the same of TSP-1, although, in some experiments, we observed a reduced ability to block migration and capillary sprouting (Fig. 4A-B) .
CD36 activation down-regulates VEGFR-2 phosphorylation
To understand the mechanisms by which CD36 negatively modulates the VEGF-A 165 signaling, we evaluated whether CD36 interfered directly with the VEGFR-2, which is the most important receptor transducing VEGF-A signals. Coimmunoprecipitation experiments between CD36 and VEGFR-2 showed that CD36 did not associate with VEGFR-2 even in presence of TSP-1 or VEGF-A 165 (data not shown). VEGFR-2 is a tyrosine kinase receptor that upon ligand binding dimerizes and autophosphorylates. When EC-CD36 were stimulated with VEGF-A 165 , the tyrosine phosphorylation of VEGFR-2 was comparable to that of EC-Pinco (Fig. 5A) . Preincubation of EC-CD36 for 15 min with TSP-1 or SMO down-regulated the tyrosine phosphorylation of VEGFR-2 stimulated by VEGF-A 165 , whereas did not modify the phosphorylation of VEGFR-2 in EC-Pinco (Fig. 5A ). EC treated with TSP-1 or SMO in absence of VEGF-A did not exhibit tyrosine phosphorylation of VEGFR-2 (Fig. 5A) . In light of biological experiments showing that point mutation on C464 of CD36 but not on C466 interferes with the effect of TSP-1, we studied VEGFR2 downstream signals in cells expressing these mutants.
EC-CD36
C466S exhibited a pattern of VEGFR-2 phosphorylation similar to that of EC-CD36 with a decreased phosphorylation in presence of TSP-1( Fig. 6A and B) . In contrast, EC-CD36 C464S did not exhibit any alterations in VEGFR-2 phosphorylation when stimulated by TSP-1 ( Fig. 6A and  B) .
A well-characterized downstream effector of VEGFR-2 is p38 mitogen-activated protein kinase (MAPK) (50, 51) . Upon VEGF-A 165 stimulation p38 MAPK was phosphorylated both in ECPinco and EC-CD36. The addition of TSP-1 or SMO reduced the level of p38MAPK phosphorylation in EC-CD36 but not in EC-pinco (Fig. 5B) . EC-CD36 C464S and EC-CD36
C466S
showed a level of p38 MAPK phosphorylation, in presence of VEGF A 165 , comparable to that of EC-Pinco and EC-CD36 (Fig. 6C ). The addition of TSP-1 reduced the VEGF-A 165 -induced phosphorylation of p38 MAPK in EC-CD36 and EC-CD36 C466S but not in EC-Pinco and EC-CD36 C464S (Fig. 6C) . In contrast, in EC-CD36 and EC-CD36
, ERK1/2 activation was not modulated by treatment with TSP-1 (Fig. 6C ).
CD36 associates with β1 integrin
Having identified C646 and R467 as two amino acids functionally involved in the CD36 signal transduction, we were interested to see whether they could single out a consensus sequence present in others transmembrane proteins and how this consensus could interact with intracellular transducers or membrane proteins. By aligning sequences beginning from the transmembrane domain, we emphasized a consensus sequence that includes C464 and R467 (Fig. 7A) . These two residues are highly conserved within CD36 and the tetraspanin family proteins that are characterized by four transmembrane domains and a short C-terminal tail (52) . Tetraspanin receptors interact with several integrins regulating the cell activities (53) . Therefore, we looked at the association between CD36 and β1 integrin in EC-CD36, EC-CD36 C464S or EC-Pinco. By coimmunoprecipitation experiments, we demonstrated that CD36 constitutively associated with β1 integrin and this interaction required C464 as inferred by the reduced association in EC-CD36
C464S
. Interestingly this association was detected exclusively when the cells were lysed in a mild detergent such as Brij97, which is a feature of tetraspanin-integrin interaction (Fig. 7B) (54, 55) . The amount of integrin β1 associated with CD36 was decreased in EC-CD36 C464S compared with EC-CD36. The specificity of association was confirmed by imuunoprecipitation with anti-β1 and immunoblot with CD36 (Fig. 7C) .
DISCUSSION
The data presented here indicate that CD36 triggered by TSP-1 inhibits EC migration and sprouting stimulated by VEGF-A 165 , a pivotal molecule of vasculogenesis and angiogenesis in embryo and adult life. VEGF-A is a potent mitogen and motogen for ECs and promotes angiogenesis in in vitro and in vivo models through binding with VEGFR-2 on ECs surface (56).
TSP-1, a natural inhibitor of vascularization both in vitro and in vivo, makes activated-ECs (13) unable to form new vessels, and thereby, in experimental animals, slows the growth of tumors (12, 17, 18, 23) . The inhibitory effect of TSP-1 on angiogenesis is reportedly due in part to CD36-mediated inhibition of EC migration and induction of apoptosis (35) . Most of these data have been generated by using bFGF, and there are few experimental details that TSP-1/CD36 could block other relevant angiogenic inducers (35, 57, 58) . Here, we demonstrate that the activation of CD36 by TSP-1 is sufficient to inhibit some biological properties of VEGF-A. Specifically, we showed that EC migration and sprouting stimulated by VEGF-A 165 were downregulated when CD36 expressed on cell surface was engaged by TSP-1 or other specific ligands such as oxLDL and agonist anti-CD36 mAb SMФ. Furthermore, TSP-1 inhibited VEGFR-2 phosphorylation in CD36-EC stimulated by VEGF-A 165 , suggesting that CD36 acts in early events of VEGF-A-induced signal cascade.
To exclude that TSP-1 inhibits VEGF-A 165 -induced in vitro angiogenesis by using different
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mechanisms rather than activation of CD36 (26, 31, 59), we transduced CD36 in ECs lacking this receptor. In fact, ECs isolated from large vessels do not express CD36 and are insensitive to TSP1 or CD36 agonist mAb SMФ (22). After transduction and expression of CD36, ECs did not show any signs of apoptosis even in presence of TSP-1. The high endogenous level of TSP-1 could explain why the EC-CD36 is insensitive to apoptosis induction by TSP-1 (60) . In contrast, EC-CD36 became sensitive to exogenous TSP-1 in chemotaxis and sprouting and did not respond to the migratory and differentiative stimulus exerted by VEGF-A 165. The inhibition of these biological activities are associated with the inhibition of phosphorylation of VEGFR-2 and p38 MAPK, which is one of downstream effectors (50, 51) . These observations, taken together with previous results obtained with bFGF (22), demonstrate that CD36 activates specific intracellular pathways that interfere with some downstream effectors of tyrosine kinase receptors. Published results showed that microvascular EC underwent to apoptosis upon treatment with TSP-1 by activating CD36, the tyrosine kinase Fyn, and p38 MAPK (35) . The signaling pathway that TSP-1 activates in HUVEC expressing CD36 seems to be an alternative signaling pathway not involved in apoptosis but in the regulation of cell migration.
We investigated how CD36 modulates EC migration and sprouting, and therefore we mutated putative key amino acids in the C-terminal cytosolic tail to gain a better understanding of the molecular determinants of CD36 involved in these processes. Mutation in the intracytoplasmic region of CD36 do not modify its binding for both TSP-1 (61) and oxLDL (41) , suggesting that the obtained results did not depend on an alteration of binding capacity of TSP-1 to ECs expressing CD36. ECs expressing CD36 mutants were analyzed for the ability to migrate and differentiate into capillary-like structure after VEGF-A 165 stimulation. In the C-terminal tail of CD36, specific protein domains or identification sequences have not been clearly identified, and therefore we mutated cysteines and basic amino acids that could be potentially involved in protein-protein interactions. Our results indicate that C464 and K469 of CD36 are required for the angiostatic activities of TSP-1. Both point mutations affect CD36 functions, and ECs carrying these mutations are refractory to the inhibitory activity of TSP-1, lasting sensitive to the chemotactic and differentiative activity of VEGF-A 165 . Point mutations in the cytoplasmic tail of C466 and R467 did not alter the TSP-1 ability to inhibit EC migration, even though EC-CD36 R467G exhibited a lack of response to TSP-1 in the sprouting assay. The TSP-1-dependent inhibition of VEGFR-2 activation was negligible in ECs carrying C464S mutant but not in those with CD36 C466S , supporting the concept that polar amino acid residues in the cytoplasmic tail of CD36 may have essential roles in the angiostatic activity of this receptor. This conclusion is also supported by the lack of inhibition exerted by TSP-1 on p38 MAPK in CD36 C464S stimulated by VEGF-A 165 . It has been demonstrated that p38MAPK is involved in the process of actin polimerization upon stimulation with VEGF-A, suggesting that reduced p38 activation in TSP-1-treated cells could lead to defective actin reorganization and motility. This is one of the first experimental observations that clearly indicate a determining role of the C-terminal tail in CD36 functions. A previous work showed a specific site on the CD36 Cterminal cytoplasmic tail that is critical for the endocytosis of oxLDL (41) .
Having identified some amino acids functionally involved in the CD36 signal transduction, we were interested to see whether they could single out a consensus sequence present in others transmembrane proteins and how this consensus could interact with intracellular transducers. By aligning sequences beginning from the transmembrane domain, we emphasized a consensus sequence that includes C646 and R467. These two residues are highly conserved within CD36 and the tetraspanin family proteins, which are characterized by four transmembrane domains and a short C-terminal tail (52) . This observation may suggest an important role of these amino acids in the biology of these proteins. Tetraspanin proteins are widely expressed transmembrane proteins involved in cellular migration, proliferation, and differentiation (53, 62) . They appear to function by regulating the activity of other receptor systems, including integrins. Recent studies indicate that CD36 associates with CD9, a tetraspanin protein, with integrins αIIbβ3, α6β1 on human platelets, and with integrins α6β1 and α3β1 on human melanoma cells (42, 63) . Dynamic regulation and localization of integrin activation play a central role in cell migration (64, 65) . Our results demonstrate that integrin β1 associates with CD36 on EC. The CD36 mutant C464S that loses the ability to inhibit EC migration showed only a residual ability to associate with integrin β1. Therefore, we may suggest that this interaction could be an important regulatory mechanism for CD36-mediated inhibition of migration. Several reports highlighted the role of integrin β1 in EC migration and identified different regulators of integrin activation (66) (67) (68) . The lateral association is one of most important mechanisms controlling spatio-temporal activation of integrins (69) . Precisely how CD36 regulate integrin function remains to be determined, but we may hypothesize that CD36 residues close to intracellular plasma-membrane regulate its lateral migration on cell surface promoting the association with integrins or recruiting adjacent integrins into membrane microdomains as suggested by Thorne et al. (42) . Moreover, because integrins are largely involved in angiogenesis and modulate the activation of VEGFR-2 (70, 71) , it is intriguing to speculate that CD36 could act as tetraspanin proteins or make supra-molecular complexes with integrins and tetraspanin that regulate the activation of VEGFR-2. The finding that TSP-1 reduces VEGFR-2 phosphorylation in ECs expressing CD36 but not in EC-CD36 C464S suggests that the complex CD36-integrin β1 could be involved in the function regulation of other membrane proteins. A recent report showed a similar mechanism for the anti-angiogenic effect of TIMP-2: TIMP-2 induced a decreased tyrosine phosphorylation of VEGFR-2 and FGFR-1, and these effects require α3β1 integrin-mediated binding of TIMP-2 to endothelial cells (72) . In conclusion, our results extend previous observations that TSP-1 inhibits bFGF effects on vascular ECs showing that its interaction with CD36 blocks functions related to angiogenesis triggered by VEGF-A. The C-terminal cytoplasmic tail of CD36 is crucial to transduce the TSP-1 signal and specific residues are necessary to its action. These amino acids are highly conserved in the tetraspanin protein family and could be involved in intracellular protein-protein interaction. Pinco (white bar) and EC-CD36 (black bar) in Boyden Chamber assay. TSP-1 (10 nM), agonist mAb SMO (1 µg/ml), and oxLDL (2 µg/ml) were tested for ability to inhibit EC-Pinco and EC-CD36 migration (means±SD; n=3). *P < 0.001 and § P < 0.005 vs. VEGF-A 165 stimulated cells. B) EC-Pinco (white bar) and EC-CD36 (black bar) were cultured in absence of serum for 24 h (SF) or in presence of VEGF-A (20 ng/ml), with or without TSP-1 (10 nM). Cell apoptosis was quantified by measuring DNA fragmentation as oligonucleosomes OD (absorbance A 405nm -A 490nm) . Values are means ± SD of 3 separate experiments performed in triplicate. C) Spheroids of ECs, embedded in collagen gel, give rise to radial outgrowing capillary sprouts in presence of VEGF-A 165 . The presence of TSP-1 (10 nM) or MoAb SMO (1 µg/ml) blocks cell sprouting from spheroids of EC-CD36 (magnification ×200). All photographs represent 3 experiments with similar results. , and CD36 C466S expression in ECs on VEGFR-2, p38 MAPK, and ERK1/2 phosphorylation. A) ECs were preincubated with TSP-1 (10 nM) or vehicle for 15 min and then stimulated with VEGF-A 165 (10 ng/ml) for 10 min or lysed and immunoprecipitated with anti-VEGFR-2 polyclonal Ab. Immunoprecipitate was analyzed by SDS-PAGE followed by immunoblotting with anti-phosphotyrosine or anti-VEGFR-2. B) Quantification by densitometry of phosphorylated VEGFR2 vs. total VEGFR2 (means±SD; n=3) *P < 0.005 vs. VEGF-A 165 stimulated cells. C) Total EC lysates treated as indicated above were assayed with anti-phospho p38MAPK and with anti-p38MAPK (upper panel), and with anti-phospho ERK1/2 and anti-ERK1/2 (lower panel). This figure represents at least 3 experiments. 
